Second-line treatment for advanced NSCLC

Size: px
Start display at page:

Download "Second-line treatment for advanced NSCLC"

Transcription

1 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello

2 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008

3 Di Maio M, EJC 2010

4 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY In 2017, second line therapy is no longer as simple We must now take into consideration: 1.Tumor histology 2.Molecular phenotype (EGFR, ALK, ROS1, etc), Cappuzzo 3.Frontline chemo components (i.e. bevacizumab) 4.Maintenance therapy (continuation, switch) 5. IO in First Line 6.Others (adequacy of tumor tissue, third party reimbursement, guidelines, pathways, etc)

5 INDUCTION MAINTENANCE 2 nd LINE 3 rd LINE

6 Di Maio M, JCO 2009

7 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Clinical Lung Cancer 2014

8 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second line therapy Outside Clinical Trials (N=464, 86% of pts progressing after first line) Gridelli C et al, J Cancer Res Clin Oncol De Marinis F et al, Clinical Lung Cancer 2014

9 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Guidelines [ESMO-AIOM]

10 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Cumulative probability Treatment Options Post-platinum Progression: Docetaxel Docetaxel was the first treatment to be approved for NSCLC patients with disease progression following first-line chemotherapy Patients receiving docetaxel 75 mg/m 2 had OS of 7.5 months, compared with 4.6 months for those receiving BSC 2 Docetaxel-treated patients had a significantly higher 1-year survival rate compared with patients receiving vinorelbine or ifosfamide (32% vs. 19%; p=.025) Docetaxel 75 mg/m 2 (n=55) BSC (n=49) Survival (months) 1. Sanofi Aventis. Taxotere (docetaxel) prescribing information. Nov Shepherd FA et al. J Clin Oncol 2000;18: Fossella FV et al. J Clin Oncol 2000;18:

11 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Survival distribution function Treatment Options Post-platinum Progression: Pemetrexed in nonsquamous NSCLC Pemetrexed was approved for patients progressing after chemotherapy after it demonstrated non-inferiority vs. docetaxel, but with a better toxicity profile 1-3 In patients with nonsquamous histology, pemetrexed treatment resulted in a median OS of 9.3 months, compared with 8.0 months for docetaxel 4 Pemetrexed is only suitable for patients with nonsquamous histology Pemetrexed Docetaxel Adjusted HR 0.78 (95% CI ) Survival (months) The increased use of pemetrexed in first-line treatment means docetaxel remains an option as subsequent therapy for patients of all histologies 1. Eli Lilly and Company. Alimta (pemetrexed) prescribing information. Sep Hanna N et al. J Clin Oncol 2004;22: Weiss GJ et al. J Clin Oncol 2006;24: Scagliotti G et al. Oncologist 2009;14:253-63

12 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Overall survival (%) Treatment Options Post-platinum Progression: Erlotinib The EGFR TKI erlotinib is approved for use in unselected patients with disease progression after first-line chemotherapy 1 However, erlotinib was inferior to docetaxel for OS and PFS in patients without an EGFR mutation; other options may be preferred in this setting 2,3 Erlotinib is not recommended for patients with a poor classification following proteomic testing in patients with WT or unknown EGFR status 3, Cox model adjusted HR 0.73 (95% CI ) Erlotinib Docetaxel Survival (months) 1. Astellas Pharma and Genentech. Tarceva (erlotinib) prescribing information. June Garassino MC et al. Lancet Oncol 2013;14: NCCN Clinical Practice Guidelines for Non-Small Cell Lung Cancer, V Gregorc V et al. Lancet Oncol 2014;15:713-21

13 PROSE Patient Flow 285 patients randomized 263 included for primary analysis 3 major protocol violations 19 never received therapy Chemotherapy (129) Erlotinib (134) VS-G 88 (68%) VS-P 41 (32%) VS-G 96 (72%) VS-P 38 (28%) The patient population was 72% male, 63% adenocarcinoma, 14% never smokers, 52% ECOG PS 0, and 41% ECOG PS 1, and was well balanced between arms. Third-line treatment at progression: CT arm: 41% overall (48% VS-G and 27% VS-P) ERL arm: 52% overall (56% VS-G and 39% VS-P) *PCR amplification/sanger sequencing of common mutations PROSE Secondary Endpoint Analysis Vanesa Gregorc, MD

14 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY

15 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY

16 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY SQUAMOUS and NON-SQUAMOUS Carcinoma: rooms for improvements

17 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Gene Methylation Mutations Translocations HYPERPLASIA DYSPLASIA CARCINOMA Air Space Limitless potential for replication INVASIVE CARCINOMA Cellular proliferation through independent growth signaling Promotion of survival signals and evasion of apoptosis Bronchial Epithelium Vascular recruitment and endothelial cell growth Tissue invasion and metastasis Adapted from Weinberg RA. Sci Am. 1996;275:62-70.

18 1:1 - Stage IV NSCLC after one platinum- based chemo +/- maintenance - Prior Bev allowed - All histologies - PS 0 or 1 R A N D O M I Z E Ramucirumab 10 mg/kg + Docetaxel 75 mg/m 2 q3wks N=628 Placebo + Docetaxel 75 mg/m 2 q3wks N=625 Treatment until disease progression or unacceptable toxicity Stratification factors: ECOG PS 0 vs 1 Gender Prior maintenance East-Asia vs. ROW Primary endpoint: Overall Survival Secondary endpoints: PFS, ORR, safety, patient-reported outcomes

19 ITT population Overall Survival (%) RAM+DOC PL+DOC Censored Median (95% CI) Censoring Rate RAM+DOC 10.5 ( ) 31.8% PL+DOC 9.1 ( ) 27.0% RAM+DOC vs PL+DOC: Stratified HR (95% CI) = ( ) Stratified log-rank P =.023 Number at risk RAM+DOC PL+DOC Survival Time (months)

20 Progression-Free Survival (%) ITT population, Investigator Assessment RAM+DOC PL+DOC Censored Median (95% CI) Censoring Rate RAM+DOC 4.5 ( ) 11.1% PL+DOC 3.0 ( ) 6.7% RAM+DOC vs PL+DOC: Stratified HR (95% CI) = 0.76 ( ) Stratified log-rank P = Number at risk RAM+DOC PL+DOC Survival Time (months)

21 Response a, n (%) Ramucirumab + Docetaxel (n=628) Placebo + Docetaxel (n=625) CR 3 (0.5) 2 (0.3) p value Ramucirumab improved ORR and DCR in nonsquamous and squamous histologies PR 141 (22.5) 83 (13.3) SD 258 (41.1) 244 (39.0) PD 128 (20.4) 206 (33.0) Unknown 98 (15.6) 90 (14.4) ORR (95% CI) 144 (22.9) ( ) 85 (13.6) ( ) <.001 DCR (95% CI) 402 (64.0) ( ) 329 (52.6) ( ) <.001

22

23 Mean ASBI Total Score Mean LCSS Total Score QoL was measured using LCSS and ASBI A similar increase in symptom burden was observed in both treatment arms n = Ramucirumab Placebo * * * * * * * * * * * * * * * * * * * * * * * * Sum 30-day vis follow-up Addition of ramucirumab had no detrimental effect on QoL * * * * * * * * * * * * * * * * * * * * * * * * Sum 30-day vis follow-up n = Cycle

24 REVEL: Patient Disposition Screened (N=1825) Randomized (ITT) Population N=1253 Excluded (n=572) Patients not receiving treatment (n=4) RAM+DOC (N=628) RAM+DOC (N=627) * wt 33% mutant 2.4% unknown 64% PL+DOC (N=625) PL+DOC (N=618) * wt 31.5% mutant 2.9% unknown 65% Patients not receiving treatment (n=4) Reasons for discontinuation (N=613) PD 341 Adverse event 94 Subject decision 90 Investigator decision 37 Death due to adverse events 30 Death from study disease 12 Other 9 On treatment at data cutoff N=11 Safety Population N=1245 Reasons for discontinuation (N=611) PD 429 Adverse event 55 Subject decision 53 Investigator decision 19 Death due to adverse events 31 Death from study disease 14 Other 10 On treatment at data cutoff N=10 *Three PL+DOC arm patients were inadvertently treated with RAM and are therefore considered part of the RAM+DOC arm for the safety analyses, but the PL+DOC arm for the ITT efficacy analysis.

25 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Forest plot PFS

26 Pembrolizumab - OS by PD-L1 expression - Keynote001 <1% 1-49% 50% 14.9% second line pts SC10.04: Second-Line Therapy and Beyond in Squamous Cell NSCLC - Silvia Novello Garon E et al, NEJM 2015

27 Pembrolizumab OS&PFS by PD-L1 expression Keynote010 HR 0.53 HR 0.76 OS most impressive in 50%, but superior with Pembrolizumab in all groups PFS benefit was superior in 50%, but not significant for either Pembrolizumab dose in 1% SC10.04: Second-Line Therapy and Beyond in Squamous Cell NSCLC - Silvia Novello Herbst R et al, The Lancet 2016

28 Keynote 010: OS by by Subgroups Pembrolizumab R Herbst et al., Lancet 2016

29 Forest plot PFS

30 Primary analysis from OAK, a randomized Phase 3 study comparing atezolizumab with docetaxel in 2L/3L NSCLC Locally advanced or metastatic NSCLC 1 2 prior lines of chemotherapy, including 1 platinum based Tumor specimen available Any PD-L1 status N=1,225 enrolled Primary endpoints (first 850 enrolled patients): OS in the ITT population OS in patients with 1% PD-L1 expression Secondary endpoints: ORR, PFS, DoR, safety Stratification factors PD-L1 expression Histology Prior chemotherapy regimens R 1:1 Atezolizumab 1200 mg IV q3w No Cross-Over Docetaxel 75 mg/m 2 q3w PD or loss of clinical benefit PD One of the largest studies that tested the role of an anti PDL-1 Mab in the setting of 2/3L NSCLC F. Barlesi, et al. ESMO Abstract LBA44_PR

31 Primary analysis from OAK, a randomized Phase 3 study comparing atezolizumab with docetaxel in 2L/3L NSCLC Overall survival (%) Characteristics Atezolizuma b n = 425 Docetaxel n = 425 Median age, y y 45% 49% Male 61% 61% Nonsquamous 74% 74% Squamous 26% 26% ECOG PS, 0/1 37%/64% 38%/62% No. of prior therapies, 1/2 History of tobacco use 75%/25% 75%/25% Never 20% 17% Current/previous Known EGFR status, % 14% / 66% 16% / 67% Mutant/WT 10% / 75% 10% / 73% Median 9.6 mo (95% CI, 8.6, 11.2) 3 Overall survival, ITT (n = 850) Atezolizumab Docetaxel HR, 0.73 a (95% CI, 0.62, 0.87) P= Minimum follow-up = 19 months Months Median 13.8 mo (95% CI, 11.8, 15.7) No. at risk Atezolizumab Docetaxel F. Barlesi, et al. ESMO Abstract LBA44_PR

32 Overall survival (%) Overall survival, PD-L1 expression OS, PD-L1 expression on 1% TC or IC TC1/2/3 or IC1/2/3; 55% of patients Median 10.3 mo (95% CI, 8.8, 12.0) HR, 0.74 a (95% CI, 0.58, 0.93) P= Minimum follow-up = 19 months OS, PD-L1 expression on 50% TC or 10% IC TC3 or IC3; 16% of patients Atezolizumab HR, 0.41 Docetaxel 100 b (95% CI, 0.27, 0.64) P< c 80 Minimum follow-up = 19 months Median 15.7 mo (95% CI, 12.6, 18.0) Median 8.9 mo (95% CI, 5.6, 11.6) Median 20.5 mo (95% CI, 17.5, NE) Months No. at risk Atezolizuma No. 1 at risk b Atezolizuma Docetaxel b Docetaxel a Stratified HR; b Unstratified HR; c P values for descriptive purpose only. TC, tumor cells; IC, tumor-infiltrating immune cells; OS, overall survival. Barlesi et al, Atezolizumab Phase III OAK Study Months F. Barlesi, et al. ESMO Abstract LBA44_PR

33 SQUAMOUS Carcinoma: rooms for improvements

34 Previous ESMO Guidelines

35

36

37

38 PFS (%) Smoking status and response to immunotherapy in NSCLC In studies of nivolumab, a history of smoking in patients with NSCLC was associated with improved clinical response and PFS PFS by smoking exposure pack-yrs smokers (mpfs 1.7 months) Variable Smoking exposure ORR, % (n/n) [95% CI] P-value >5 pack-yrs smokers (mpfs 2.2 months) HR (95% CI) = 0.41 (0.22, 0.74), P = pack-yrs >5 pack-yrs 0 (0/14) [0, 23] 30 (20/66) [20, 43] pack-yrs smokers >5 pack-yrs smokers Months Since Treatment Initiation HR = hazard ratio; mpfs = median progression-free survival; ORR = objective response rate; PFS = progression-free survival. Hellmann MD, et al. Poster presented at ESMO 2014 (asbtr. 1229PD).

39 SC10.04: Second-Line Therapy and Beyond in Squamous Cell NSCLC - Silvia Novello Campbell JD et al, Nat Genet 2016

40 Randomize 1:1 CheckMate 017 (NCT ) - Study Design Stage IIIb/IV SQ NSCLC NIVO 3 mg/kg IV Q2W, until PD or unacceptable toxicity n = 135 Primary: OS Secondary: Endpoints Investigator-assessed ORR 1 prior platinum doublet-based chemotherapy ECOG PS 0 1 N = 272 DOC 75 mg/m 2 IV Q3W, until PD or unacceptable toxicity n = 137 Investigator-assessed PFS Correlation between PD-L1 expression and efficacy (ORR, OS, PFS), Quality of life (LCSS) DBL: December 15, 2014 At time of DBL, 199 deaths (of 272 randomized pts) were reported (86% of 231 deaths required for final analysis) The boundary for declaring superiority for OS at the pre-planned interim analysis was P <0.03 DBL, data base lock; ECOG PS = Eastern Cooperative Oncology Group performance status; IV = intravenous; LCSS = lung cancer symptom scale; PD = progressive disease; PD-L1 = programmed cell death ligand 1; SQ = squamous; Q2W = every 2 weeks; Q3W = every 3 weeks Brahamer J et al, NEJM 2015

41 Checkmate 017: Updated follow-up Reckamp K et al., WCLC 2015 ORAL 02.01

42 Checkmate 017: Updated follow-up Reckamp K et al., WCLC 2015 ORAL 02.01

43 OS and PFS Hazard Ratios by PD-L1 Status PD-L1 expression Patients, n NIVO DOC Unstratified HR(95% Cl) OS 1% (0.45, 1.05) <1% (0.37, 0.92) 5% (0.31, 0.89) <5% (0.47, 1.02) 10% (0.28, 0.89) <10% (0.48, 1.01) Not quantifiable at baseline (0.19, 0.82) PFS 1% (0.44, 1.01) <1% (0.43, 1.00) 5% (0.32, 0.90) <5% (0.52, 1.08) 10% (0.33, 1.02) <10% (0.49, 0.99) Not quantifiable at baseline (0.23, 0.89) Spigel DR et al, ASCO 2015 NIVO DOC

44 Forest plot PFS

45 Is there a room for targeted therapies (WITHOUT target) in SQUAMOUS carcinoma SC10.04: Second-Line Therapy and Beyond in Squamous Cell NSCLC - Silvia Novello

46 Lux Lung 8: Study design Stratified by East Asian vs. Non-East Asian SCC of the lung (Stage IIIB/IV) 1 Progressed after 4 cycles of a first-line platinum doublet ECOG PS 0 1 Adequate organ function 1:1 Afatinib 40 mg QD Erlotinib 150 mg QD Primary Endpoint: PFS by Independent Review Key secondary Endpoint: Overall Survival Other secondary Endpoints: ORR, DCR, tumor shrinkage, PRO, safety Dose escalation to 50 mg and dose reduction to 30 or 20 mg permitted Dose reduction to 100 or 50 mg permitted Tumor assessment at baseline, Weeks 8, 12, 16; every 8 weeks thereafter. 1. American Joint Committee on Cancer staging manual 7th edition Soria JC et al, ASCO 2015

47 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Events, % LUX LUNG 8: Safety Afatinib (n=392) Erlotinib (n=395) Any AE Drug-related AEs AEs leading to dose reduction AEs leading to discontinuations CTCAE grade 3 or higher Serious AEs Drug-related fatal AEs 1.5 Afatinib 1.3 Erlotinib (N=392) (N=395) AE category, % All Grade 3 Grade 4 All Grade 3 Grade 4 Total with related AEs Diarrhea <1 Rash/acne* Stomatitis* Fatigue* Nausea Decreased appetite Paronychia* <1 0 Dry skin Pruritus 8 < Vomiting Dehydration Goss GD IASLC Geneva 2015; Soria JC et al, ASCO 2015

48 LUX LUNG 8: Efficacy OS Forest plot PFS PFS SC10.04: Second-Line Therapy and Beyond in Squamous Cell NSCLC - Silvia Novello Soria JC et al, Lancet Oncol 2015

49 For Patients and Caregivers -A 60-page booklet in English, designed as an information guide for patients with SqCLC -The most frequent key questions from a patient with SqCLC

50 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY ADENOCarcinoma ( non-squamous ): rooms for improvements

51 LUME-Lung 1 Study Design Stage IIIB/IV or recurrent NSCLC patients after 1 st line chemotherapy (all histologies) R A N D O M I Z E 1:1 Nintedanib 200mg BID p.o., D2 21, + Docetaxel 75mg/m 2 IV, D1, 21-day cycles (n=655) Placebo BID p.o., D2 21, + Docetaxel 75mg/m 2 IV, D1, 21-day cycles (n=659) PD PD N=1314 Number of docetaxel cycles not restricted Monotherapy allowed after 4 cycles of combination therapy Stratification: ECOG PS (0 vs 1) Prior bevacizumab (yes vs no) Histology (squamous vs nonsquamous) Brain metastases (yes vs no) Primary end point: PFS Next analysis step only allowed if PFS confirmed with all PFS events at time point of OS analysis RECK LBA8011, ASCO 2013

52 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY LUME1: PFS TOTAL population ADENOCARCINOMA SQUAMOUS CARCINOMA Reck M et al, Lancet Oncol 2014

53 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY LUME1: OS Adenocarcinoma <9mo ADENOCARCINOMA Total population Reck M et al, Lancet Oncol 2014

54 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY LUME1: Safety Reck M et al, Lancet Oncol 2014

55 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Forest plot PFS

56 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY CheckMate 057: Non Squamous pts Stage IIIB/IV NON-SQUAMOUS NSCLC 1 prior platinum doublet ECOG PS 0 1 Pre-treatment (archival or recent) tumor samples required for PD-L1 analysis Prior maintenance therapy allowed Prior TKI therapy allowed for known ALK translocation or EGFR mutation N = 582 Randomize 1:1 Nivolumab 3 mg/kg IV Q2W until PD or unacceptable toxicity n = 292 Docetaxel 75 mg/m 2 IV Q3W until PD or unacceptable toxicity n = 290 Patients stratified by prior maintenance therapy and line of therapy (second- vs third-line) Primary Endpoint OS Additional Endpoints ORR b PFS b Safety Efficacy by tumor PD-L1 expression Quality of life (LCSS) NIVOLUMAB NON SQ CHECK-MATE 057 (1) OS RR(%) Median (mos) 1-yr (%) PRETREATED III/IV PS0-1 NIVO 292 PTS DOC 290 PTS p= HR Borghaei h et al, NEJM 2015 Sep 27

57 UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Take Home Messages Chemotherapy is still present in second line NSCLC advanced patients Antiangiogenic copound found a second youth in second line Immunotherapy plays a relevant role in this setting.at least until it will move to first line Today even more than yesterday is crucial to design a treatment algorithm for these patients not to waste therapeutic approaches

58

Second-line treatment for advanced NSCLC

Second-line treatment for advanced NSCLC Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017 Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in

More information

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not

More information

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato

Nivolumab: esperienze italiane nel carcinoma polmonare avanzato NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale

More information

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma

Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca

More information

NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza

NSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine

More information

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute

Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts

More information

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in

More information

Maintenance paradigm in non-squamous NSCLC

Maintenance paradigm in non-squamous NSCLC Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons

More information

PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER

PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for

More information

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

Practice changing studies in lung cancer 2017

Practice changing studies in lung cancer 2017 1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received

More information

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University

2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University 2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling

More information

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective

Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive

More information

Incorporating Immunotherapy into the treatment of NSCLC

Incorporating Immunotherapy into the treatment of NSCLC Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

Patient Selection: The Search for Immunotherapy Biomarkers

Patient Selection: The Search for Immunotherapy Biomarkers Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic

More information

Immune checkpoint blockade in lung cancer

Immune checkpoint blockade in lung cancer Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data

More information

Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle

Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout

More information

Squamous Cell Carcinoma Standard and Novel Targets.

Squamous Cell Carcinoma Standard and Novel Targets. Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:

More information

Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung

Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone

More information

Medical Treatment of Advanced Lung Cancer

Medical Treatment of Advanced Lung Cancer Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics

More information

Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento

Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara

More information

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy

Slide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University

More information

NSCLC with squamous histology: Current treatment and new options on horizon

NSCLC with squamous histology: Current treatment and new options on horizon NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New

More information

Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer

Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Immunotherapeutic Advances in the Treatment of Metastatic Non-Small Cell Lung Cancer Srinivasa R. Sanikommu, MD, and Kathryn F. Mileham, MD Abstract Lung cancer remains the leading cause of cancer-related

More information

Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018

Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,

More information

Take home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone

Take home message. Emilio Bria. II SESSIONE: Immunoterapia nel tumore del polmone II SESSIONE: Immunoterapia nel tumore del polmone Take home message Emilio Bria Oncologia, Dipart. di Medicina, Università di Verona, Az. Osp. Univ. Int., Verona emilio.bria@univr.it Roma, 28 Marzo 2017

More information

Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer

Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Updates From the European Lung Cancer Conference: Immunotherapy and Non-Small Cell Lung Cancer Benjamin Besse, MD, PhD Chair, EORTC Lung Group Chair, Gustave Roussy Thoracic Unit Villejuif, France What

More information

Immunoterapia di 1 linea Evidenze e Prospettive Future

Immunoterapia di 1 linea Evidenze e Prospettive Future Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures

More information

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?

Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive

More information

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf

MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance

More information

Carcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona

Carcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007

More information

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer

Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern

More information

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program

More information

Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit?

Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Considerations for Choosing TKIs for Squamous NSCLC in the Era of Immunotherapy: Which Patients Could Benefit? Barbara Melosky University of British Columbia, British Columbia Cancer Agency Faculty Disclosure

More information

Largos Supervivientes, Tenemos datos?

Largos Supervivientes, Tenemos datos? Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot

More information

INNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy

INNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK

More information

Treatment of EGFR mutant advanced NSCLC

Treatment of EGFR mutant advanced NSCLC Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M

More information

Understanding Options: When Should TKIs be Considered?

Understanding Options: When Should TKIs be Considered? Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis

More information

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual

More information

Immunotherapy in Patients with Non-Small Cell Lung Cancer

Immunotherapy in Patients with Non-Small Cell Lung Cancer LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings

More information

Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab

Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori

More information

Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC

Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim

More information

Treatment of EGFR mutant advanced NSCLC

Treatment of EGFR mutant advanced NSCLC Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation

More information

The road less travelled: what options are available for patients with advanced squamous cell carcinoma?

The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting

More information

Quale sequenza terapeutica nella malattia EGFR+

Quale sequenza terapeutica nella malattia EGFR+ Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with

More information

1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC

1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC 1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science

More information

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,

More information

Alessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona

Alessandro Inno. IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Verona GRUPPO C Coordinatore: Diego Signorelli Ruolo dei checkpoint inhibitors nelle neoplasie polmonari: le evidenze scientifiche e l inserimento dei checkpoint inhibitors nell algoritmo decisionale del NSCLC

More information

Sao Paulo, Abril 2014

Sao Paulo, Abril 2014 Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use

More information

ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine

ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from

More information

Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung

Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung 2017 Conversations in Oncology in Shanghai, China Prof. Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital Affiliated to Medical

More information

VEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany

VEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck

More information

Recent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO

Recent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University

More information

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?

Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology

More information

1st line chemotherapy and contribution of targeted agents

1st line chemotherapy and contribution of targeted agents ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy

More information

Immunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington

Immunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =

More information

Checkpoint Inibitors for Bladder Cancer

Checkpoint Inibitors for Bladder Cancer Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,

More information

in combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4

in combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4 Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small

More information

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents

Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center

More information

Lung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.

Lung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive. Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents

More information

Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs

Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor

More information

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,

More information

IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC Vassiliki A. Papadimitrakopoulou, 1 Manuel Cobo, 2 Rodolfo Bordoni, 3 Pascale

More information

Non-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT

Non-Small Cell Lung Cancer Webinar. Thursday, September 13, p.m. EDT Non-Small Cell Lung Cancer Webinar Thursday, September 13, 2018 1 2 p.m. EDT 1 2 Webinar Faculty Julie R. Brahmer, MD Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Patrick Forde, MD Johns

More information

Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)

Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis

More information

Chemotherapy for Advanced Gastric Cancer

Chemotherapy for Advanced Gastric Cancer Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,

More information

Maintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017

Maintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy

More information

Immune checkpoint inhibitors in NSCLC

Immune checkpoint inhibitors in NSCLC 1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?

More information

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy

More information

Targeted Therapies for Advanced NSCLC

Targeted Therapies for Advanced NSCLC Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting

More information

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates. 6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes

More information

Sequencing in EGFR-Mutated NSCLC: Does Order Matter?

Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,

More information

Recent Therapeutic Advances for Thoracic Malignancies

Recent Therapeutic Advances for Thoracic Malignancies Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation

More information

EGFR Mutation-Positive Acquired Resistance: Dominance of T790M

EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin

More information

Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction

Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation

More information

Lead team presentation:

Lead team presentation: Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain

More information

Immunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary

Immunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary 01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss

More information

Atezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1

Atezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1 Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson

More information

Algoritmo de tratamiento del CNMP escamoso. Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla

Algoritmo de tratamiento del CNMP escamoso. Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla Algoritmo de tratamiento del CNMP escamoso Jesús Corral, MD Thoracic Oncology Unit HUVR-Oncoavanze, Sevilla Agenda CNMP escamoso vs no escamoso: diferencias? Opciones de tratamiento 1L Opciones de tratamiento

More information

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012

LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),

More information

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )

Sponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere ) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Immunotherapy in NSCLC

Immunotherapy in NSCLC Immunotherapy in NSCLC Enriqueta Felip Hospital Vall d Hebron University, Barcelona SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, January 27 217 Immunotherapy in NSCLC: Outline 1 st line as

More information

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.

Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer. Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor

More information

Improving outcomes for NSCLC patients with brain metastases

Improving outcomes for NSCLC patients with brain metastases Improving outcomes for NSCLC patients with brain metastases Martin Schuler West German Cancer Center, Essen, Germany In Switzerland, afatinib is approved as monotherapy for patients with non-small cell

More information

Recent Advances in Lung Cancer: Updates from ASCO 2017

Recent Advances in Lung Cancer: Updates from ASCO 2017 Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017

More information

Opzioni terapeutiche nel paziente ALK-traslocato

Opzioni terapeutiche nel paziente ALK-traslocato Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali

More information

Angiogenesis and tumor growth

Angiogenesis and tumor growth Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis

More information

K-Ras signalling in NSCLC

K-Ras signalling in NSCLC Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer

More information

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage

More information

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director

More information

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,

More information

Principles and Application of Immunotherapy for Cancer: Advanced NSCLC

Principles and Application of Immunotherapy for Cancer: Advanced NSCLC In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged

More information

Introducción. Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol

Introducción. Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol Introducción Enric Carcereny ICO Badalona-Hospital Germans Trias i Pujol Introducción Cáncer de pulmón: la neoplasia más frecuente y la principal causa de muerte relacionada con el cáncer. GLOBOCAN 2012

More information

CURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff

CURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,

More information

Cancer Cell Research 14 (2017)

Cancer Cell Research 14 (2017) Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of

More information